Phase III. Phase III shall consist of the monitoring of the construction of the Project to ensure that the work is installed in accordance with the requirements of the Construction Documents and all applicable codes and regulations. This phase includes monitoring and management, as appropriate, of all change orders and pay requests, and the implementation of the building assurance program established in the Using Agency’s Program. Major Deliverables: Review/recommendation on GMP Change Order Review/recommendation on Change Orders Review/recommendation on DP invoices Review/recommendation on CM/GC Pay Applications Periodic Construction IAW Design Reviews Periodic Cost Analysis Updates Professional Services: Engineering and design review services Budget and costing services Project management services
Phase III. If GEM elects to participate in Phase III, it shall pay to Ohio Triangle, within ten (10) days of receipt by Ohio Triangle of GEM’s written election to participate, the sum of Two Hundred Thousand And No/100 Dollars ($200,000.00) as the third and final payment of the initial Lease costs (“Third Lease Payment”). Said payment shall be via wire transfer of immediately available funds to the banking coordinates identified, in writing by Ohio Triangle. Subject to Section 9.16, GEM’s failure to pay timely shall cause this Agreement to terminate and become null and void as between the Parties.
Phase III. The collective bargaining agreement (CBA) process begins. Initially affected employees and/or secondarily affected employees may then exercise their rights under the CBA. The CBA process ends when either (1) the affected employee(s) has a comparable job; or (2) the affected employee(s) choose to waive further contractual displacement rights and enter Phase III.
Phase III. Within thirty (30) days following the date on which Celltech first administers any Licensed Product to a human subject in a Phase III Clinical Trial on a Licensed Product, Celltech shall pay NeoGenesis [*]. "Phase III Clinical Trial" shall mean any clinical study in any Major Country of a Licensed Product, the primary purpose of which is evaluating statistical significance of the safety and efficacy of the Licensed Product in patients with the disease target being studied as required by the relevant Regulatory Authority to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling.
Phase III. As used herein, “Phase III” shall mean Verification of Design, including acceptance testing of LSR Instrument Prototypes.
Phase III. Tenant shall pay Base Rent for Phase III Expansion Premises in accordance with the following: Annual Base Rent Monthly Base Rent 3/1/13 - 2/28/14 $ 197,894.55 $ 16,491.21 3/1/14 - 2/28/15 $ 202,987.05 $ 16,915.59 3/1/15 - 2/28/16 $ 208,079.55 $ 17,339.96 3/1/16 - 2/28/17 $ 213,172.05 $ 17,764.34 3/1/17 - 2/28/18 $ 218,264.55 $ 18,188.71 3/1/18 - 4/30/19 $ 223,357.05 $ 18,613.09 Anything to the contrary notwithstanding, Tenant shall not be required to pay Base Rent or Additional Rent for the first eight (8) months of the Term for Phase III Expansion Premises.
Phase III. Upon Commencement of the first Phase III trial in the United States, Europe or Japan by SuperGen for the first therapeutic clinical candidate covered under the Licensed Patents, not necessarily restricted to cancer indications, SuperGen will pay to Licensor the sum of one million five hundred thousand U.S. dollars ($1,500,000) in cash or SuperGen stock along with piggyback registration rights therefor. Upon Commencement of Phase III trial in the United States, Europe or Japan by SuperGen for subsequent therapeutic clinical candidates covered under the Licensed Patents, SuperGen will pay to Licensor the sum of seven hundred and fifty thousand U.S. dollars ($750,000) in cash or SuperGen stock along with piggyback registration rights therefor. In the event SuperGen undertakes a Phase II/III clinical trial , then Commencement of such Phase II/III trial, and not of a Phase III trial, shall trigger the payment described in this section. A Phase II/III trial is defined as a pivotal study in which a therapeutic clinical candidate is being tested in humans for safety and efficacy in an expanded patient population at geographically dispersed clinical sites on the basis of which SuperGen will seek regulatory approval in lieu of a Phase III trial. Determination that a clinical trial is a Phase II/III shall be exclusively by SuperGen after conferring with the appropriate regulatory authority. Commencement (“Commencement”) is defined as the dosing of the first patient under a protocol involving a therapeutic clinical candidate covered under the Licensed Patents, not necessarily restricted to cancer indications.
Phase III. Subject to and in accordance with the following provisions, Landlord shall fully construct the base building on a “turnkey basis” in accordance with the Preliminary Base Building Plan, including, without limitation, floor plans, elevations and site plan(s) outlined in Exhibit B-5 attached hereto and made a part hereof (collectively, the “Phase III PBBP”) and the Base Building Outline Specification attached hereto as Exhibit B-6 , and made a part hereof (collectively, the “Phase III Outline Specifications”; all of such work described in the Phase III PBBP and in the Phase III Outline Specifications, as the same may be supplemented or modified in accordance with the following provisions, shall be collectively referred to herein as the “Phase III Landlord’s Work”). In the event of differences between the Phase III PBBP or the Phase III Landlord’s Plans (as hereinafter defined) and the Phase III Outline Specifications, the Phase III Outline Specifications shall govern and control until the Phase III Landlord’s Plans (as hereinafter defined) are prepared. Landlord represents and warrants to Tenant that the Phase III Landlord’s Plans shall comply with all Legal Requirements and shall achieve a LEED rating of Gold Certified Core & Shell status under LEED 2009. Tenant acknowledges that the free standing parking structure depicted on Exhibit A-7 is subject only to Tenant’s review of the aesthetics and capacity thereof and Landlord warrants that it shall be constructed in substantial conformance to Exhibit A-7. Landlord shall construct the tenant improvements on a “cost-plus basis” in accordance with the Phase III Tenant’s Plans and Phase III TI Outline Specifications, as such terms are defined below. To permit Tenant’s Architect to prepare a complete set of construction plans (the “Phase III Tenant’s Plans”) and specifications (the “Phase III TI Outline Specifications”) for all of the tenant improvements for Phase III (all of such work described on the Tenant’s Phase III Plans and in the Phase III TI Outline Specifications shall be collectively referred to herein as the “Phase III Tenant’s Work”), Landlord shall, at Landlord’s sole cost and expense, cause to be prepared a complete set of final base building plans and construction drawings and specifications conforming in all material respects to the Phase III PBBP, such drawings and specifications to include a detail schedule of core base building finish items such as, but not limited to, carpets, doors, hardware, ...